tbuckley/cabot-search huggingface dataset:
P4-16-06: Expression Patterns of Receptor Activator of Nuclear Factor-kB (RANK) and Src in a Series of Primary Breast Tumors (BT) and Bone Metastases (BM) in Patients (pts) with Metastatic Breast Cancer (MBC).
Authors: A Gucalp, E Comen, S Redana, L Evangelista, DD Giri, XH Zhang, S Patil, M Akram, L Norton, CA Hudis, MN Fornier
Journal: Cancer Research (2011)

Abstract Background BM develops in 65–70% of pts with MBC. RANK and its ligand (RANK-L) can be critical in the development and progression of BM. Src overexpression and deregulation occurs in many solid tumors but it has not been fully characterized although an association between Src activity defined by a gene expression signature and BM particularly in ER+ pts has been described. (Zhang XH et al. Cancer Cell. 2009) Our goal was to elucidate the relationship between Src and RANK expression in BT and BM in relation to estrogen-/progesterone-receptor (ER/PR)/HER2 expression and tumor histology (invasive ductal carcinoma (IDC) vs invasive lobular carcinoma (ILC)). Methods: Immunohistochemistry (IHC) for RANK (R&amp;D Systems clone 80707) and Src (Cell Applications Inc. Phospho Tyr-416) protein expression was performed on archived paraffin embedded BT and BM. Scoring: 0=negative, 1+=weak, 2+=intermediate, 3+=strong and the percent of positive tumor cells; RANK+ = 2–3+, &amp;gt; 1% of cells; Src+ = 1–3+; &amp;gt; 1% of cells. Associations between RANK/Src expression and tumor characteristics were assessed using the chi-square test or McNemar's test for pairs, as appropriate. Results: From the MSKCC database, using an IRB-approved waiver of consent, we identified 54 pts with MBC who underwent surgical biopsy of a metastatic bone lesion at our center between 2005–2010, and had tissue available for further testing. 17 corresponding BT samples were identified. At the time of diagnosis, 43 (79.5%) primary tumors were ER or PR (+); 6 (11%) were HER2+; 41 (76%) were invasive ductal carcinoma. 87% of BM expressed RANK and 44% expressed Src. (Table 1) No significant correlation between RANK or Src expression in BM and ER/PR/HER2 status of BT was observed. A significant correlation between RANK expression and BT histology was observed, (p=0.0016): 93% of IDC were RANK (+), in comparison to 50% of invasive lobular carcinomas. RANK expression was not significantly different between primary tumor and metastatic bone samples (p=0.99). There was a borderline significant difference in Src expression between primary and metastatic site (p=.06). Conclusions: In our cohort, no correlation between RANK or Src by IHC and ER/PR/HER2 was identified but RANK expression was more common in IDC than ILC. Fidelity was high for RANK between primary and metastatic lesions while Src expression may possibly vary. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-16-06.
Avulsion of the papilla of Vater managed using a rendezvous technique and extra-anatomic drainage
Authors: Ludivine Legros, Emmanuel Quehen, Guillaume Bouguen, Jean-François Bretagne
Journal: Endoscopy (2013)

While recommendations exist for the surgical management of pancreaticoduodenal injuries according to their seriousness [1], the recommended management of avulsion of the papilla of Vater has not been clearly defined [2] [3]. Here we describe the first reported case of avulsion of the papilla of Vater being managed by endoscopy using a rendezvous technique.
I-123 Metaiodobenzylguanidine Myocardial Scintigraphy in a Patient with Brugada Syndrome
Authors: Tsutomu Kawasaki, Tatsuro Kaminaga, Daisuke Hirota, Haruo Mitani, Shigeru Furui
Journal: Clinical Nuclear Medicine (2001)

Kawasaki, Tsutomu M.D.; Kaminaga, Tatsuro M.D.; Hirota, Daisuke M.D.; Mitani, Haruo M.D.; Furui, Shigeru M.D. Author Information
OC-154 Inter-observer agreement for manometry classification of individual swallows and diagnoses using high-resolution manometry (HRM) with esophageal pressure topography (EPT): results of high participation web-based studies by the HRM working group
Authors: M R Fox, J Pandolfino, J Jafari, D Menne
Journal: Gut (2012)

<h3>Introduction</h3> Recently the HRM Working Group presented a classification system for esophageal motility disorders using HRM/EPT (Pandolfino, NGM 2009). This study reports inter-observer agreement for classification of individual HRM/EPT water swallows (study A) and diagnoses based on 10 swallows (study B) using this system. <h3>Methods</h3> All registered members of the hrmconsensus.org website were invited to take part. Institution and experience with HRM were recorded. A sample of 147 individual swallows (study A) and 40 diagnostic studies (study B) was reviewed and classified using a drop down menu that utilised the published system. The on-line platform provided a generic EPT format with fixed pressure scale and time base. Contours facilitated analysis of intra-bolus and contractile pressure; however no data summary was provided. The sequence of swallows was fixed for each user, but randomised between users to avoid sequence bias. Users were blinded to other participant9s entries. During the study users were free to reclassify and post comments; however, once completed classifications could not be changed. <h3>Results</h3> (A) All 147 individual swallows were assessed by 18 users. High levels of agreement (≤2/18 dissenters) were present for normal peristalsis and achalasia but lower levels for peristaltic and intra-bolus pressure (IBP) abnormalities. (B) All 40 diagnostic studies were assessed by 36 users. Overall inter-observer agreement was fair (κ 0.42) being higher (κ&gt;0.5) for aperistalsis and achalasia, and lower (κ&lt;0.4) for peristaltic abnormalities. Users with &gt;400 HRM/EPT studies showed somewhat better agreement (n=9; κ 0.46) and agreement was good for users in the US institution that developed the classification system (n=4; κ 0.57). Analysis of comments revealed that disagreements in both studies were not random but due to (1) multiple abnormalities in single swallows (2) limited functionality of on-line software/lack of a data summary that confounded user9s ability to distinguish closely related diagnoses, especially those that depend on precise pressure measurement. <h3>Conclusion</h3> This is the largest assessment of inter-observer agreement performed for manometric studies. Overall inter-observer agreement for HRM/EPT of individual swallows and diagnostic studies was moderate, increasing with experience of this technology and the classification system. Analysis of swallows with low agreement indicate that “pattern recognition” of HRM/EPT was not adequate and highlighted the value of objective metrics in diagnosis of esophageal dysmotility. <h3>Competing interests</h3> M Fox consultant for: given imaging, paid instructor for: Sandhill MMS, J Pandolfino: None declared, J Jafari: None declared, D Menne: None declared.
SP0041 MRI in Psoriatic Arthritis - From Spine to Toes
Authors: K. G. Hermann
Journal: Annals of the Rheumatic Diseases (2013)

<h3></h3> Psoriatic arthritis (PsA) is one of the most exciting joint diseases. The clinical appearance of PsA is very diverse, involving the spine, sacroiliac joints, peripheral joints and entheses. Consequently, also imaging findings vary and in many cases only the combined interpretation of X-rays, ultrasound, CT and MRI will lead to the correct diagnosis. Research teams have tried to use MRI for further differentiation from rheumatoid arthritis or hand osteoarthritis, e.g. with the help of dynamic contrast-enhanced MRI, pattern recognition or single-joint high-resolution MRI. Those studies so far did not reveal distinct features for PsA to differentiate it from other inflammatory arthritides. The lecture will highlight typical findings in PsA on MRI from a clinical radiology perspective and will correlate these with X-ray findings and differential diagnoses as appropriate. The participants will learn how to use MRI in distinct situation in the diagnostic workup of patients with suspected PsA. Furthermore, new developments in quantifying disease activity will be presented. <h3>Disclosure of Interest</h3> K. G. Hermann Paid instructor for: Pfizer, MSD, AbbVie
SAT0261 Correlations among enthesitis, clinical, radiographic and quality of life parameters in patients with ankylosing spondylitis
Authors: A. Rezvani, S.E. Demir
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Enthesitis is a primary clinical feature in Ankylosing spondylitis (AS). It is an inflammatory process that affects the site of insertion of ligaments and tendons into bone. Elevated enthesitis scores were reported to be associated with worse outcomes in patients with AS. <h3>Objectives</h3> This study was performed to investigate the relation between enthesitis and disease activity, functional status, fatigue, joint mobility, radiological damage, laboratory parameter and quality of life in patients with AS. <h3>Methods</h3> A total of 421 patients with AS (323 men and 98 women) who included in the Turkish League Against Rheumatism Registry were enrolled in the study. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), fatigue, the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Metrology Index (BASMI), the Maastricht Ankylosing Spondylitis Enthesitis Score (MASES), AS quality of life (ASQoL), the Bath Ankylosing Spondylitis Radiology Index (BASRI) and ESR were evaluated. <h3>Results</h3> The mean ages and disease duration were 39.66±10.81years and 12.05±0.70 months, respectively. Enthesitis was present in 27.3% and absent in 72.7% of patients with AS. There was a positive correlation between MASES and BASDAI (p&lt;0.001), MASES and BASFI (p&lt;0.001) and also MASES and fatigue (p&lt;0.01). MASES was negatively correlated with disease duration and body mass index (BMI) (p:0.017 and p:0.047 respectively). MASES was not correlated with age, BASRI, BASMI, ASQoL and ESR (p&gt;0.05). The mean number of MASES was 1.15±2.40. The most frequent regions of enthesopathies were right iliac crest, spinous process of L5, proximal to the insertion of left achilles tendon, left iliac crest, left first costochondral jointrespectively. <h3>Conclusions</h3> Enthesitis was found to be associated with higher disease activity, higher functional status and higher fatigue, lower disease duration and lower BMI. However, we could not find any association between enthesitis and joint mobility, radiological damage, quality of lifeand laboratory parameter. <h3>References</h3> Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewé R, van ver Tempel H, Mielants H, Dougados M, van der Heijde D. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis. 2003 Feb;62(2):127-32. Sengupta R, Stone MA. The assessment of ankylosing spondylitis in clinical practice. Nat Clin Pract Rheumatol. 2007 Sep;3(9):496-503. Vastesaeger N, van der Heijde D, Inman RD, Wang Y, Deodhar A, Hsu B, Rahman MU, Dijkmans B, Geusens P, Vander Cruyssen B, Collantes E, Sieper J, Braun J. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis. 2011 Jun;70(6):973-81. <h3>Disclosure of Interest</h3> None Declared
612 COGNITIVE DYSFUNCTION IS ASSOCIATED WITH POOR SOCIO-ECONOMIC STATUS IN CIRRHOSIS IN AN INTERNATIONAL, MULTI-CENTER STUDY
Authors: O. Riggio, N. Piazza, E. Onori, R. Prakash, S. Allampati, S. Montagnese, P. Amodio, K.D. Mullen, N.A. Noble, M.B. White, J.S. Bajaj
Journal: Journal of Hepatology (2012)
Usefulness and limitatin of contrast-enhanced power Doppler EUS for diagnosis of pancreatic diseases
Authors: M Kitano, H Sakamoto, K Maekawa, Y Suetomi, T Nishio, Y Takeyama, T Chikugo, M Kudo
Journal: Endoscopy (2006)

Aims: Our purpose is to assess usefulness of contrast-enhanced power Doppler EUS (CE-EUS) for depiction and differential diagnosis of pancreatic tumors, as compared with contrast-enhanced harmonic US (CE-US) and contrast-enhanced CT (CE-CT). Subjects and methods: Consecutive 119 patients with suspicious pancreatic tumors received CE-CT, CE-EUS and CE-US. Coded phase-inversion harmonic mode (GE Logiq 9) which depicts signals from bubbles in fine vessels was used for CE-US. Power Doppler mode was used for CE-EUS (OLYMPUS GF-UC240P-AL5). Levovist was employed as the ultrasound contrast agent for CE-US and CE-EUS. CE-CT was imaged 30 and 60 seconds after the injection of contrast media. Sensitivities in depicting tumors and in differetiating ductal carcinomas from the other tumors were compared between the 3 modalities. Results: When hypovascular nodules relative to their surrounding tissue were defined as ductal carcinomas, the sensitivity on CE-EUS (69%) was significantly lower than those on CE-CT (82%) and CE-US (88%). However, values for sensitivity in depicting small pancreatic tumors of 2cm or less on CE-US (91%) and EUS (95%) were significantly higher than that on CE-CT (56%). Concerning to those small tumors, the values for sensitivity in differentiating ductal carcinomas from the other tumors were 40%, 73% and 67% on CE-CT, CE-US and CE-EUS, respectively. EUS depicted 7 of 9 ductal carcinomas that CE-CT failed to depict, 5 of which were hypovascular on CE-EUS. Conclusion: Although CE-EUS has limitation in differentiating pancreatic tumors due to artifact such as blooming and overpainting, it may be useful for differential diagnosis of small nodules of the pancreas which the other modalities failed to depict. The invention of the technology of contrast-enhanced harmonic EUS would further improve the abilities in depicting and differentiating small tumors.
Primary Diagnosis of Multiple Pheochromocytomas in the Brother of a MEN-2 Patient by Simultaneous MIBG Scintigraphy and Low-Dose Computed Tomography
Authors: Andreas Kjaer, Claus Leth Petersen
Journal: Clinical Nuclear Medicine (2002)

Metaiodobenzylguanidine (MIBG) scintigraphy is a well-established functional imaging method for localizing pheochromocytomas. However, the morphologic information revealed on the scintigram is often too sparse and thus, accordingly, supplemental computed tomography (CT) or magnetic resonance imaging are often performed. Recently, gamma cameras with built-in low-dose CT were introduced. The authors describe a patient with a high likelihood of pheochromocytoma who had simultaneous MIBG scintigraphy and low-dose CT performed as the primary examinations. The scan revealed pheochromocytomas in both adrenal glands and one extra-adrenal pheochromocytoma located in the liver. The combined imaging ensured the final diagnosis without any need for further imaging. Based on the findings of this case, the authors believe that combined MIBG scintigraphy and low-dose CT is a promising future single imaging technique for pheochromocytomas.
Abstract 4887: FTY720 prevent tumorigenesis and suppress the progression of colitis-associated cancer.
Authors: Akimitsu Yamada, Jie Liang, Masayuki Nagahashi, Eugene Y. Kim, Kuzhuvelil B. Harikumar, Wei-Ching Huang, Nitai C. Hait, Jeremy C. Allegood, Megan M. Price, Dorit Avni, Tomasz Kordula, Milstien Sheldon, Kazuaki Takabe, Sarah Spiegel
Journal: Cancer Research (2013)

Abstract Inflammatory bowel disease is an important risk factor for colorectal cancer. Sphingosine-1-phosphate (S1P), a pleiotropic bioactive sphingolipid metabolite formed by two sphingosine kinases, SphK1 and SphK2, is involved in inflammation and cancer. Enhanced tumor number and size, with a concomitant increase in tumor load was observed in mice overexpressing SphK1 treated with the colonotropic mutagen azoxymethane (AOM) followed by three rounds of oral administration of the luminal toxin dextran sodium sulfate (DSS) to induce colitis-associated cancer (CAC). There was also a large increase in adenomas with a high grade of dysplasia associated with increased SphK1 expression and formation of S1P. We demonstrated that the SphK1/S1P axis is important for production of IL-6 and is involved in persistent activation of STAT3 and consequent upregulation of one of its target genes, the S1P receptor S1PR1. Because the pro-drug FTY720 modulates the immune system by acting as a functional antagonist of S1PR1, inducing its internalization and degradation, we examined its effect on CAC progression. FTY720 drastically reduced colitis-associated tumorigenesis, when it was administered during CAC induction. Remarkably, FTY720 blocked CAC progression even when it was administered later after the last DSS treatment when tumors were already established. Moreover, it reduced SphK1 expression, production of IL-6, and persistent activation of STAT3. These findings suggest that FTY720 may be beneficial for preventing tumor formation in individuals with inflammatory bowel disease. This work was supported by grants from the National Institute of Health (R37GM043880, R01CA61774, U19AI077435 to S.S. and R01CA160688 to K.T.). M.N. is a Japan Society for the Promotion of Science Postdoctoral Fellow. Citation Format: Akimitsu Yamada, Jie Liang, Masayuki Nagahashi, Eugene Y. Kim, Kuzhuvelil B. Harikumar, Wei-Ching Huang, Nitai C. Hait, Jeremy C. Allegood, Megan M. Price, Dorit Avni, Tomasz Kordula, Milstien Sheldon, Kazuaki Takabe, Sarah Spiegel. FTY720 prevent tumorigenesis and suppress the progression of colitis-associated cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4887. doi:10.1158/1538-7445.AM2013-4887
Abstract C70: Integrative analysis of pharmacologic, genomic, and transcriptomic assays in cancer
Authors: Manway Liu, Anupama Reddy, Alan Huang, Giordano Caponigro, Joseph Lehar
Journal: Cancer Research (2011)

Abstract We describe an integrative analysis approach leveraging the publicly available Cancer Cell Line Encyclopedia to uncover regulatory pathways in cancer. Six different lines of evidence are considered in identifying candidate factors associated with disease: 1) gene mutation status, 2) copy number variations, 3) RNAi growth inhibitions, 4) pharmacological growth inhibitions, 5) baseline gene expression data, and 6) physical protein-protein interactions. As each of these evidence sources measure a different aspect of cellular regulation, they may be considered in combination to uncover regulatory mechanisms associated with tumorigenesis. For example, gene mutation status or copy number variation data may be combined with baseline gene expressions to identify genes that are differentially expressed in cell lines with aberrant or deactivated versions of specific tumor suppressors and oncogenes. To assess our approach, we applied it to identification of genes involved in the well-known RAS-RAF regulatory signaling pathway in both tissuespecific and nonspecific contexts. The RAS-RAF signaling pathway plays a key role in cellular differentiation and proliferation and is frequently associated with tumorigenesis. Specifically, we identified differentially expressed genes in BRAF mutant vs. wild-type cell lines, genes associated with high and low RAF copy number alteration cell lines, genes correlating in expression to growth inhibition by RAF-targeting compounds, and genes that either rescue or sensitize cell lines to BRAF knockdown by RNA interference. We further considered these genes within the overall context of physical interactions between their protein products. Highlighting the significant, research potential of our approach, our RAF-focused analysis identified both well-known and novel genes, supported by different lines of evidence, that mediate RAS-RAF signaling across multiple tissues. Positive control genes include members of the classical pathway, such as MAPK1, MAP2K1, and PI3K. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the Second AACR International Conference on Frontiers in Basic Cancer Research; 2011 Sep 14-18; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2011;71(18 Suppl):Abstract nr C70.
Clinical Guidelines: Implementing Them Won't Be Easy
Authors: C. McNeil
Journal: JNCI Journal of the National Cancer Institute (1996)

Newster," he said, "but we're worried that this may not be enough.Tumors have many ways to make themselves invisible to immune attack."And, he continued, "There have been very few randomized studies."Most of the promising data comes from phase II trials that compare a small number of vaccinated patients to historical controls."The problem is that there may be a fair amount of selection bias.The group receiving the vaccine is probably selected in some way that makes them appear to do better regardless of whether you treat them or not," said Sznol.Randomized phase ITI trials are the only way to really test the effectiveness of vaccines.For some, like Morton, who after 20 years of failure is confident about the effectiveness of his vaccine, that's a painful reality.He said he loses sleep at night because half the patients in the trials will receive only a placebo -a salt solution -instead of the vaccine."But there is no way the FDA will accept the vaccine without doing a trial.Unless you're willing to have your work subject to the scientific discipline of clinical trials, you should be in private practice treating everybody by intuition," he said.And if none of the six vaccines in phase HI trials prove effective, there are 30 more in the pipeline.So where's the beef?Stay tuned.
Effect of Atenolol on Mortality and Cardiovascular Morbidity after Noncardiac Surgery
Authors: Dennis T. Mangano, Elizabeth L. Layug, Arthur Wallace, Ida Tateo
Journal: New England Journal of Medicine (1996)

Perioperative myocardial ischemia is the single most important potentially reversible risk factor for mortality and cardiovascular complications after noncardiac surgery. Although more than 1 million patients have such complications annually, there is no effective preventive therapy.
TCT-557 Carotid Artery Stenting with Double Cerebral Embolic Protection in Symptomatic Patients
Authors: Ferdinando Varbella, Francesco Tomassini, Andrea Gagnor, Alfonso Gambino, Paolo Giay Pron, Massimo Hartwig, Monica Reggiani, Salvatore Amarù, Emilio Luda di Cortemiglia
Journal: Journal of the American College of Cardiology (2014)